- Home
- AMC vs IMCR Comparison
AMC vs IMCR Comparison
Compare AMC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMC
- IMCR
- Stock Information
- Founded
- AMC 1920
- IMCR 2008
- Country
- AMC United States
- IMCR United Kingdom
- Employees
- AMC N/A
- IMCR N/A
- Industry
- AMC Movies/Entertainment
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMC Consumer Discretionary
- IMCR Health Care
- Exchange
- AMC Nasdaq
- IMCR Nasdaq
- Market Cap
- AMC 1.5B
- IMCR 1.5B
- IPO Year
- AMC 2013
- IMCR 2021
- Fundamental
- Price
- AMC $3.01
- IMCR $31.34
- Analyst Decision
- AMC Hold
- IMCR Buy
- Analyst Count
- AMC 7
- IMCR 10
- Target Price
- AMC $3.92
- IMCR $58.13
- AVG Volume (30 Days)
- AMC 13.7M
- IMCR 560.7K
- Earning Date
- AMC 08-01-2025
- IMCR 08-07-2025
- Dividend Yield
- AMC N/A
- IMCR N/A
- EPS Growth
- AMC N/A
- IMCR N/A
- EPS
- AMC N/A
- IMCR N/A
- Revenue
- AMC $4,548,300,000.00
- IMCR $333,581,000.00
- Revenue This Year
- AMC $8.36
- IMCR $26.82
- Revenue Next Year
- AMC $6.63
- IMCR $8.15
- P/E Ratio
- AMC N/A
- IMCR N/A
- Revenue Growth
- AMC N/A
- IMCR 25.75
- 52 Week Low
- AMC $2.45
- IMCR $23.15
- 52 Week High
- AMC $5.76
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- AMC 43.56
- IMCR 40.28
- Support Level
- AMC $3.08
- IMCR $35.10
- Resistance Level
- AMC $3.54
- IMCR $37.56
- Average True Range (ATR)
- AMC 0.13
- IMCR 1.74
- MACD
- AMC -0.06
- IMCR -0.79
- Stochastic Oscillator
- AMC 5.17
- IMCR 0.75
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.